

Novel Influenza Work Group

Jon Temte, MD, MS, PhD

Advisory Committee on Immunization Practices

29Oct2014

Rationale

- Two FDA-licensed H5N1 vaccines
 - Need for recommendations for use during inter-pandemic period
 - Need to review evidence for use in certain people who have an increased risk of exposure
- ACIP was seen as the most appropriate body to develop recommendations for these vaccines
- Seasonal influenza work group focuses on seasonal influenza vaccines (full plate)

Background

- ACIP Work Group formed February 2014
- Charged with developing recommendations for use of influenza A (H5N1) vaccine during inter-pandemic period

Work Group

Organization	Organization
ACIP Members Doug Campos-Outcalt Ruth Karron Jon Temte	Chair Chair, Influenza Work Group Chair, ACIP
Liaisons Kathy Neuzil Matthew Zahn	IDSA NACCHO
Consultants Wendy Keitel John Treanor Rick Bright	BARDA
<i>Ex Officio</i> Members Jesse Geibe Marion Gruber Linda Lambert, Kanta Subbarao, Catherine Luke, Alison Kraigsley Bruce Gellin	DoD FDA NIH NVPO

Policy Question

- Should licensed influenza A (H5N1) vaccine be recommended to adults with increased risk of exposure during the inter-pandemic time period?
 - If yes
 - Define exposure
 - Define recommendation

Progress and Next Steps

- Feb - Oct 2014: 11 Work Group meetings
- October 2014 ACIP meeting
 - Data presentations (Sonja Olsen, CDC lead for WG)
 - Influenza A (H5N1) epidemiology and vaccine
 - GRADE and policy options for influenza A (H5N1) vaccine
- February 2015 ACIP
 - Present recommendation for a vote